Hanna Rosenbaum Selected Research

Glucosylceramidase (Glucocerebrosidase)

8/2015	Impaired migration capacity in monocytes derived from patients with Gaucher disease.
2/2015	Management of women with Gaucher disease in the reproductive age.
12/2014	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
10/2014	Hemorrhagic aspects of Gaucher disease.
11/2013	Hypercoagulability, parkinsonism, and Gaucher disease.
11/2011	Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
11/2005	Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation.
11/2004	Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
1/2002	Cholelithiasis in patients with Gaucher disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hanna Rosenbaum Research Topics

Disease

24	Gaucher Disease (Gaucher's Disease) 09/2023 - 01/2002
4	Anemia 09/2023 - 01/2002
3	Cytopenia 02/2015 - 11/2013
2	Rare Diseases (Rare Disease) 01/2020 - 01/2011
2	Thrombocytopenia (Thrombopenia) 01/2019 - 10/2014
2	Pulmonary Hypertension 02/2015 - 11/2013
2	Parkinson Disease (Parkinson's Disease) 11/2005 - 11/2004
1	Splenomegaly 01/2019
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2016
1	Body Weight (Weight, Body) 12/2014
1	Hypersensitivity (Allergy) 11/2011
1	Hemolysis 04/2010
1	Multiple Myeloma 09/2007
1	Parkinsonian Disorders (Parkinsonism) 11/2004
1	Gallstones (Gallstone) 01/2002
1	Cholelithiasis 01/2002

Drug/Important Bio-Agent (IBA)

9	Glucosylceramidase (Glucocerebrosidase)IBA 08/2015 - 01/2002
7	eliglustatIBA 01/2019 - 08/2010
6	taliglucerase alfaIBA 09/2023 - 11/2011
5	Glucosylceramides (Glucocerebrosides)IBA 08/2015 - 01/2002
4	EnzymesIBA 08/2015 - 01/2002
2	Hemoglobins (Hemoglobin)IBA 09/2023 - 11/2010
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2016
2	imiglucerase FDA Link 01/2016 - 12/2014
1	Biosimilar PharmaceuticalsIBA 01/2020
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018
1	HDL LipoproteinsIBA 01/2018
1	oxidized low density lipoproteinIBA 01/2018
1	Azacitidine (5 Azacytidine)FDA Link 10/2016
1	Lenalidomide (CC 5013)FDA Link 10/2016
1	GlucosidasesIBA 12/2014
1	CeramidesIBA 10/2014
1	Hemostatics (Antihemorrhagics)IBA 10/2014
1	Blood Coagulation Factors (Coagulation Factor)IBA 10/2014
1	Glucose (Dextrose)FDA LinkGeneric 10/2014
1	Immunoglobulin G (IgG)IBA 11/2011
1	ceramide glucosyltransferaseIBA 08/2010
1	AntioxidantsIBA 04/2010
1	fermented papaya preparationIBA 04/2010
1	Immunoglobulins (Immunoglobulin)IBA 09/2007

Therapy/Procedure

10	Enzyme Replacement Therapy 09/2023 - 11/2010
7	Therapeutics 01/2019 - 08/2010
1	Splenectomy 01/2002
1	Cholecystectomy 01/2002